Organization (Industry)
Scilex Pharmaceuticals, Inc. (United States)
ClinicalTrials.gov lists Scilex Pharmaceuticals, Inc. (United States) as lead sponsor of 15 trials. It has 4 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Scilex Pharmaceuticals, Inc. (United States): 15 lead-sponsored trials and 3 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 5 |
| Neuralgia | 3 |
| Sciatica | 3 |
| Hirsutism | 2 |
| Hypertrichosis | 2 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2007 | 2 |
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SP-103 | Back Pain | Phase 2 | 1 |
| SP-103 | Hypotension | Phase 2 | 1 |
| SP-103 | Pain | Phase 2 | 1 |
| SP-103 | Low Back Pain | Phase 2 | 1 |
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Lidocaine | 6 |
| Dronabinol | 2 |
| Diclofenac Gel | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 1 of 3 on time (n=3) |
Journals published in (16)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of pain research | 5 |
| Acta ortopedica brasileira | 1 |
| American journal of physical medicine & rehabilitation | 1 |
| Annals of rehabilitation medicine | 1 |
| BMC musculoskeletal disorders | 1 |
Showing 5 of 16 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 9 | 4 | 2025-04-29 |
SEC-reported annual financials (7)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 30,253,000 | -374,053,000 | 20,710,000 |
| 2024 | 56,590,000 | -72,807,000 | 9,641,000 |
| 2023 | 46,743,000 | -114,331,000 | 12,746,000 |
| 2022 | 38,034,000 | -23,364,000 | 9,054,000 |
| 2021 | 31,317,000 | -88,424,000 | 9,201,000 |
| 2020 | 23,560,000 | -47,519,000 | 9,961,000 |
| 2019 | not reported | not reported | not reported |
Financing and grant events (401)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-18 | Other financing | not disclosed | Sec extracted |
| 2026-07-03 | Private placement | not disclosed | Sec extracted |
| 2026-07-03 | Private placement | not disclosed | Sec extracted |
| 2026-06-24 | Other financing | not disclosed | Sec extracted |
| 2026-05-04 | Other financing | not disclosed | Sec extracted |
Showing 5 of 401 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Worldwide Clinical Trials (United States) | Co sponsors trial with | 4 |
| Worldwide Clinical Trials (United States) | Uses vendor | 3 |
| Cromos Pharma LLC | Co sponsors trial with | 1 |
| John Papakonstantinou, MD | Co sponsors trial with | 1 |
| Syngene | Co sponsors trial with | 1 |
Latest dated events (430)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-18 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-03 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-03 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-24 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 430 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| LBP | Trial sponsor | Named in trial inclusion criteria |
| LBP | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.